AMERICAN ACADEMIC PUBLISHER

INTERNATIONAL JOURNAL OF MEDICAL SCIENCES

ISSN NUMBER: 2692 - 5206 Volume 5. No 11. November ,2025

NSAID-INDUCED GASTROINTESTINAL ULCER DISEASE: MECHANISM, PREVALENCE, AND PREVENTION

Nuriddinov Umed Zayniddin ugli
Asia International University, Bukhara, Uzbekistan

Introduction

Nonsteroidal anti-inflammatory drugs (NSAIDs) represent one of the most widely prescribed and over-the-counter drug categories worldwide. They are integral to the management of pain, inflammation, and fever in medical specialties such as rheumatology, orthopedics, neurology, and general practice. Despite their clinical utility, prolonged or inappropriate use of NSAIDs is associated with a spectrum of gastrointestinal (GI) toxicities, ranging from mild gastritis to severe peptic ulcer disease and life-threatening bleeding or perforation. This paper explores the mechanisms, epidemiological burden, and prevention of NSAID-induced gastrointestinal ulcer disease.

Pathogenesis (Mechanism of Development)

The pharmacodynamic basis of NSAID-induced GI injury centers on the inhibition of cyclooxygenase (COX) enzymes—COX-1 and COX-2—which are responsible for prostaglandin synthesis. Prostaglandins maintain homeostatic functions in the GI tract, including mucosal protection and repair, as well as modulation of acid secretion.

COX Type	Physiological Role	Primary Function	Effect of Inhibition
COX-1	Constitutively expressed in most tissues	Produces protective prostaglandins (PGE_2, PGI_2) maintaining mucosal defense and blood flow	Loss of mucosal protection, increased susceptibility to injury and bleeding
COX-2	Induced during inflammation	Generates prostaglandins involved in inflammatory pain and swelling	Reduction of inflammation and pain but minimal mucosal impact

Inhibition of COX-1 leads to decreased prostaglandin synthesis (notably PGE_2 and PGI_2), triggering the following pathophysiological effects:

1. Reduced secretion of mucus and bicarbonate, exposing the gastric mucosa to acid-induced damage.

AMERICAN ACADEMIC PUBLISHER
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
ISSN NUMBER: 2692 - 5206 Volume 5. No 11. November ,2025

2. Decreased mucosal blood flow and impaired epithelial regeneration.

3. Relative increase in gastric acid production due to disrupted feedback mechanisms.

4. Direct epithelial toxicity via uncoupling of mitochondrial oxidative phosphorylation, particularly observed with non-selective agents like aspirin, indomethacin, and naproxen.

In addition to local effects, NSAIDs can also induce small intestinal injury (NSAID enteropathy), resulting in occult bleeding, iron deficiency anemia, and protein loss. These multifactorial mechanisms contribute cumulatively to ulcer formation and its complications.

Incidence (Epidemiological Overview)
Epidemiological studies indicate that between 10% and 30% of chronic NSAID users exhibit endoscopic evidence of gastric or duodenal mucosal injury. Approximately 2–4% develop symptomatic peptic ulcers or clinically significant gastrointestinal bleeding annually. The relative risk of upper GI bleeding among NSAID users is estimated to be 4–5 times greater than in non-users. Risk escalates sharply in elderly individuals (≥60 years), in patients using corticosteroids, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs).

Recent meta-analyses suggest that NSAID-related GI complications are responsible for an estimated 15,000–30,000 deaths annually worldwide, with hospitalizations for NSAID-induced bleeding ulcers exceeding 100,000 cases each year in developed nations.

Clinical Manifestations
NSAID-induced ulceration often progresses silently until complications occur. When symptomatic, patients may experience:

- Epigastric discomfort, dyspepsia, or burning pain after meals

- Nausea, vomiting, or early satiety

- Hematemesis (vomiting blood) or melena (black tarry stools) due to upper GI bleeding

- Fatigue or dizziness secondary to chronic anemia

Complicated ulcers can present with acute hemorrhage, perforation, or gastric outlet obstruction, each requiring urgent medical intervention.

Prevention Strategies
Several pharmacological and non-pharmacological approaches have been developed to mitigate NSAID-induced GI injury:

1. Proton Pump Inhibitors (PPIs): PPIs such as omeprazole, esomeprazole, and pantoprazole are highly effective in reducing gastric acidity, thereby promoting mucosal healing and protection. They are strongly recommended for elderly or high-risk NSAID users.

2. Selective COX-2 Inhibitors: Drugs such as celecoxib, etoricoxib, and meloxicam preferentially inhibit COX-2, sparing COX-1 and thus minimizing GI toxicity. However, caution is advised due to potential cardiovascular adverse effects.

AMERICAN ACADEMIC PUBLISHER
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
ISSN NUMBER: 2692 - 5206 Volume 5. No 11. November ,2025

3. Misoprostol (Prostaglandin E_1 Analog): Misoprostol replenishes prostaglandin activity, enhancing mucosal resistance. While effective, it often causes diarrhea and abdominal cramping, limiting patient adherence.

4. Combination Therapy: Co-prescription of PPIs or misoprostol with NSAIDs markedly reduces ulcer risk. Fixed-dose combinations such as naproxen/esomeprazole are now available.

5. Lifestyle and Dosing Modifications: Utilizing the minimal effective dose, avoiding alcohol and smoking, and taking NSAIDs after meals can substantially lower GI injury risk.

6. Alternative Analgesics: In some cases, acetaminophen or topical NSAIDs may be substituted to reduce systemic exposure.

Conclusion

NSAIDs remain essential therapeutic agents in the management of pain and inflammation. Nevertheless, inhibition of COX-1 impairs the protective gastric prostaglandin barrier, increasing susceptibility to ulceration and bleeding. Proactive risk assessment and preventive strategies—including co-administration of PPIs, selective COX-2 inhibitors, or prostaglandin analogs—are crucial for patient safety. Education regarding dose minimization, appropriate co-therapy, and early symptom recognition further enhances treatment outcomes.

References:

1. Lanas A, Chan FKL. Peptic ulcer disease. Lancet. 2017;390(10094):613–624.

2. Cryer B, Feldman M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used NSAIDs. Am J Med. 1998;104(5):413–421.

3. Wallace JL. Mechanisms, prevention and clinical implications of NSAID-enteropathy. World J Gastroenterol. 2013;19(12):1861–1876.

4. Bhatt DL et al. Expert consensus on reducing GI risks of antiplatelet therapy and NSAID use. J Am Coll Cardiol. 2008;52(18):1502–1517.

5. Lichtenberger LM, Zhou Y, Jayaraman V. NSAID injury to the GI tract: evidence, mechanisms, and prevention. Curr Opin Gastroenterol. 2022;38(6):589–597.

6. Yeomans ND. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs: New insights and preventive strategies. Med J Aust. 2019;210(3):106–111.

7. Scheiman JM, Fendrick AM. Summing the risk of NSAID therapy. Lancet. 2007;369(9573):1580–1581.

8. Scarpignato C et al. Safe prescribing of NSAIDs: A consensus statement. Dig Liver Dis. 2018;50(9):991–1001.